Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $83.65 USD
Change Today -0.1336 / -0.16%
Volume 1.8M
LLY On Other Exchanges
Symbol
Exchange
New York
Mexico
SIX Swiss Ex
Sao Paulo
EN Paris
Frankfurt
As of 1:03 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

eli lilly & co (LLY) Snapshot

Open
$84.50
Previous Close
$83.78
Day High
$84.57
Day Low
$83.53
52 Week High
06/11/15 - $87.24
52 Week Low
08/7/14 - $60.14
Market Cap
92.9B
Average Volume 10 Days
6.6M
EPS TTM
$2.63
Shares Outstanding
1.1B
EX-Date
08/12/15
P/E TM
31.8x
Dividend
$2.00
Dividend Yield
2.36%
Current Stock Chart for ELI LILLY & CO (LLY)

eli lilly & co (LLY) Details

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of major depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products for the treatment of erectile dysfunction and benign prostatic hyperplasia, thrombotic cardiovascular events, and cardiac ischemic complications. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine, cattle, and poultry; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases, as well as controls intestinal parasite infections in dogs. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; chronic allergic dermatitis and kidney diseases in cats. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

39,135 Employees
Last Reported Date: 02/19/15
Founded in 1876

eli lilly & co (LLY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $1.0M
Executive Vice President of Science & Technol...
Total Annual Compensation: $1.0M
Senior Vice President and President of Lilly ...
Total Annual Compensation: $682.9K
General Counsel and Senior Vice President
Total Annual Compensation: $765.0K
Compensation as of Fiscal Year 2014.

eli lilly & co (LLY) Key Developments

Immunocore Limited and Eli Lilly and Company Enters Clinical Trial Collaboration in Melanoma

Immunocore Limited and Eli Lilly and Company announced that they have entered into an immunotherapy-based clinical trial collaboration to explore the utility of Immunocore’s lead T-cell receptor based investigational therapeutic, IMCgp100, in combination with Lilly’s galunisertib (LY2157299) and merestinib (LY2801653) for the treatment of melanoma. The goal of the collaboration is to identify combination regimens that provide synergies in efficacy and durability in patients with metastatic cutaneous and uveal melanomas. Under the terms of the agreement, Immunocore and Lilly will conduct a Phase Ib/II clinical study evaluating the safety and preliminary efficacy of IMCgp100 in combination with galunisertib in metastatic cutaneous melanoma. A second Phase Ib/II study will be conducted combining IMCgp100 with merestinib in metastatic uveal melanoma. Lilly will act as trial sponsor. These studies are anticipated to begin in 2016. No financial terms were disclosed. IMCgp100 and galunisertib are members of a new class of cancer treatments known as immunotherapies, which are designed to enhance the body’s own immune system in fighting cancer and whose mechanisms of action have the potential to be complementary. IMCgp100 is Immunocore’s most advanced Immune mobilising mTCR Against Cancer molecules (ImmTAC), which are a novel class of bi-specific biologic drugs based on T-cell receptors (TCRs) with ultra-high affinity for intracellular and extracellular cancer targets. Lilly’s galunisertib is a small molecule inhibitor of TGF beta R1 kinase that in vitro selectively blocks TGF beta signaling. TGF beta promotes tumor growth, suppresses the immune system and increases the ability of tumors to spread in the body. Merestinib is Lilly’s small molecule multi-kinase inhibitor that in vitro selectively blocks signaling of MET, MST1R (RON), AXL, and MKNK1/2.

Adocia and Eli Lilly Report Positive Phase 1b Topline Results on the Post-Meal Effect of Ultra-Rapid BioChaperone Lispro in Patients with Type 1 Diabetes

Adocia and Eli Lilly and Company announced the completion of a Phase 1b clinical trial evaluating BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Lilly. This formulation uses Adocia’s proprietary technology BioChaperone, which is designed to accelerate insulin absorption. This completed study, part of the Adocia-Lilly partnership, aimed to compare the effects of BioChaperone Lispro and Humalog® (insulin lispro rDNA origin) when injected at mealtime on post-prandial glycemic control in type 1 diabetes patients. While commercialized fast-acting insulin analogs are injected five to 15 minutes before or immediately after a meal, an ultra-rapid insulin may allow injection at the time of the meal, or even after the start of a meal while improving post-prandial glycemic control. In this crossover, randomized, double-blind meal study, 38 people with type 1 diabetes received a 0.2 U/kg dose of either BioChaperone Lispro or Humalog just prior to a standardized meal. The primary endpoint was a comparison of the post-meal glycemic excursions over the first two hours (Delta-AUC-BG(0-2h)). BioChaperone Lispro was associated with a 61% reduction in post-prandial glucose excursion over the first two hours compared to Humalog (Delta-AUC-BG(0-2h) ratio = 0.39; 95%-CI 0.28 to 0.52; p<0.0001). The study also provides confirmation of the ultra-rapid pharmacokinetic profile of BioChaperone Lispro. These results are consistent with previous clinical findings from NCT021466511 demonstrating BioChaperone Lispro has a significantly faster rate of insulin lispro absorption than Humalog with an increase in the early insulin exposure of 168% at the same dose (AUClispro_0-30min ratio = 2.68; 95%-CI 2.18 to 3.30; p<0.0001). In terms of safety, BioChaperone Lispro and Humalog led to similar numbers of hypoglycemia episodes. No local reactions were seen on the site of administration for either treatment.

Eli Lilly and Sarah Cannon Research Institute Partner to Co-Develop New Cancer Therapy

Eli Lilly and Company and Sarah Cannon Research Institute have announced a strategic partnership to co-develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway. The partnership supports the development of this novel targeted cancer therapy, including flexible and efficient program design and implementation, as well as more rapid patient enrollment to clinical trials by accessing SCRI's large network of patients.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:US $83.60 USD -0.18

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.04 USD +0.03
AbbVie Inc $67.01 USD -0.17
Amgen Inc $152.34 USD +0.74
Bristol-Myers Squibb Co $66.17 USD +0.195
Medtronic PLC $74.00 USD +0.70
View Industry Companies
 

Industry Analysis

LLY

Industry Average

Valuation LLY Industry Range
Price/Earnings 42.0x
Price/Sales 4.7x
Price/Book 6.1x
Price/Cash Flow 43.5x
TEV/Sales 4.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit www.lilly.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.